Aureka Biotechnologies has secured $35 million in Series A+ funding, led by Sequoia China, with participation from existing and new investors. The company plans to use these funds to enhance its AI-driven antibody design platform, AuraIDE™, and its underlying foundation models and agent capabilities. Aureka aims to accelerate drug discovery by integrating its wet-lab experimental platforms with AI to create rapid feedback loops, significantly reducing the traditional 5-10 year validation cycle for new drug candidates. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Accelerates AI-driven drug discovery timelines and validates the commercial potential of AI in pharmaceutical development.
RANK_REASON Significant funding round for an AI-driven biotech company.